Ask Question
Sign Guest book

 
About Lymphoma
| Advocacy & Art | CAM & Life Style | Clinical trials | Doctors & Centers  | Guidelines  at  Diagnosis | How  to   Help  | Research | Side Effects  | Support | Symptoms  | Tests | Treatments


WebCasts

Clinical Trials of Interest - First Line Low Toxic

  

Clinical TrialsClinical Trials of Interest > First Line, Low Toxic

Last update: 03/08/2008

> First Line Low Toxic  | First Line Primary Therapy | Relapsed / refractory | Addressing other unmet needs

First line Low Toxic (with minimal toxicity)

"First line" means as first therapy

Goal:
Managing indolent lymphomas with minimal toxicity; maintaining future treatment options.

Also see Locating First Line Therapies for Lymphoma 

 

 

New: Fenretinide* and Rituxan

Condition:
B-cell lymphomas, including CLL

Rationale and goal:  "Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving fenretinide together with rituximab may kill more cancer cells. 

PURPOSE: This phase I/II trial is studying the side effects and best dose of fenretinide and to see how well it works when given together with rituximab in treating patients with B-cell non-Hodgkin's lymphoma."


* Fenretinide (4-HPR) is a retinoid (vitamin A) analogue with antitumor and chemopreventive activities.  In a mouse model, Fenretinide showed synergy with Rituxan.  

TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape | PubMed
TOPIC SEARCH Safety or Toxicity -  PubMed 

 

Rituxan followed by Maintenance (regularly scheduled) Rituxan
 
Condition: previously untreated stage III or IV NHL with low tumor burden.

Rationale and goal:  (1) manage lymphoma with fewer side effects with an immune-based therapy that is considered less toxic than chemotherapy and might be less likely than chemotherapy to preclude future treatment options; 

(2) compare different maintenance schedules of Rituxan to see which, if any, provide a clinical advantage; 

(3) identify biological markers that may predict who is most likely to benefit optimally from Rituxan. 
TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape | PubMed
TOPIC SEARCH Toxicity - Medscape | PubMed 

 

Enzastaurin  
 
Condition:
Previously untreated follicular NHL in watchful waiting status

Rationale and goal:  To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in patients with Follicular Lymphoma.. 


TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape | PubMed
TOPIC SEARCH Safety or Toxicity -  PubMed 

Orally administered protein kinase C-beta (PKCbeta) inhibitor Source

Also see NEWS: http://www.docguide.com/news/
 

 

 

Idiotype vaccine administered with GM-CSF- Genitope.com 

 
Condition:
Previously untreated patients with CLL in watchful waiting status

Rationale and goal:  The treatment being investigated is rId-KLH, a patient- and tumor-specific therapy known as a personalized immunotherapy. Personalized immunotherapy uses a person’s own immune system in an attempt to combat disease. Sargramostim (a.k.a. GM-CSF) is given together with the personalized immunotherapy because it may enhance the effect. 


TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape | PubMed
TOPIC SEARCH Safety or Toxicity -  | PubMed 
 

 
Rituxan and Denileukin Diftitox 
  
Condition: Previously untreated Stage III or IV Follicular NHL

Rationale and goal:  Monoclonal antibodies, such as Rituxan, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. 

Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to cancer cells. Giving rituximab together with denileukin diftitox may kill more cancer cells.

 

 
Biaxin-Based Antibiotic
 
Condition: Untreated advanced stage indolent Lymphoma

Rationale and goal:  ... to see if a treatment with Biaxin (clarithromycin) which is an antibiotic given by mouth for 3 months can delay the growth of your lymphoma or shrink the lymphoma. We would also like to see how Biaxin (clarithromycin) works on lymphoma and blood cells. There is some evidence that this medication may change the behavior of lymphocytes, in addition to its known anti-infection activity.
 
  First Line Low Toxic  | First Line Primary Therapy Relapsed / refractory | > Addressing other unmet needs

Addressing Other Unmet Needs: 

TYPE: None-Interventional

Genomic and Biobank | Outcomes and Toxicities | Quality of Life | Screening Tests and Imaging

TOPIC SEARCH: Queries of ClinicalTrials.gov for Lymphoma (none interventional types)

 

Genomic and Biobank Studies
Genome Expression Study (highly recommended when it's time for a biopsy)

Rationale: The observed variability in the clinical course of follicular lymphoma, along with the diverse range of therapeutic options available, necessitates accurate prognostic stratification of the individual patient.

Conditions: Lymphoma; Leukemia; Multiple Myeloma; Lymphoid Malignancies

Locations: 
  Nebraska Medical Center in Omaha,  
  Southwest Oncology Group centers- see for centers http://www.swog.org/ 
  the British Columbia Cancer Agency in Vancouver, Canada; 
  the Norwegian Radium Hospital in Oslo, Norway; 
  the University of Würzburg in Würzburg, Germany; 
  the University of Barcelona in Barcelona, Spain; and 
  St. Bartholomew's Hospital in London, England.

Background:  The Leukemia and Lymphoma Molecular Profiling Project (LLMPP), a collaboration of researchers in the United States, Canada, and Europe NCI investigators are working with researchers at the University of Nebraska Medical Center in Omaha to define the gene expression profiles of all types of human lymphoid malignancies. 

The project is supported by an international collaboration ...  The LLMPP uses "Lymphochip" cDNA (complementary DNA) microarrays, which are enriched in genes that are expressed in and/or function in lymphocytes. Lymphochip microarrays allow measurement of the RNA expression levels of the represented genes. Gene expression profiles developed as a result of this project may someday be used for disease classification (diagnosis), prognosis, and therapy selection. Already, results from the LLMPP indicate that these profiles can improve diagnostic accuracy and provide prognostic information. 

The LLMPP is initiating a multicenter clinical trial to evaluate a lymphoma diagnostic chip, called LymphDX, which was designed by the company Affymetrix in collaboration with NCI researchers using LLMPP data. The study will demonstrate the feasibility of disseminating the LymphDX microarray technology to all of the participating sites and will also evaluate the diagnostic utility of the LymphDX chip in a prospective study.
Source: cancer.gov  
Genetic Study of Chronic Lymphocytic Leukemia Families
Condition: CLL 
Location: U.T.M.D. Anderson Cancer Center, Houston,  Texas
Genetic Studies of X-Linked Lymphoproliferative Disease
Conditions: X-Linked Lymphoproliferative Disease; Lymphoproliferative Disease; Genetic Diseases, X-Linked
 
Outcomes and Toxicities
An Observational Study of Treatment, Outcomes, and Prognosis 
Condition: Lymphoma, Non Hodgkin
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients 
Condition: Non-Hodgkins Lymphoma
Prospective Data Collection of Newly Diagnosed Cases
Conditions: Hodgkin Disease; Lymphoma, Non-Hodgkin
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).
Condition: Hodgkin Lymphoma
Study of Late-Occurring Complications in Childhood Cancer Survivors
Condition: Cancer
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
Condition: Cancer
Quality of Life
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; ...
Nutritional Assessment Intervention to Improve Cancer-Related Fatigue
Conditions: Leukemia; Lymphoma; Fatigue
Screening Tests and Imaging
Dual Time Point PET Imaging in Lymphoma
Condition: Hodgkin's or Non-Hodgkin's Lymphoma
Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials
Conditions: Brain and Central Nervous System Tumors; Lymphoma

 

 

Return to top

 

 
Disclaimer:  The information presented on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.